Abstract:ABSTRACT Objectives: Cerebrolysin is a nootropic drug that directly affects cerebral neurons due to its unique neurotrophic activities. This study evaluated the efficacy and safety of cerebrolysin in patients with mild to moderately severe vascular dementia. Methods: The trial was a multicentre, double-blind, parallel-group design. 148 patients aged 55 to 85 years were randomised to treatment with either cerebrolysin 30 ml or placebo intravenous infusion once daily from Monday to Friday for four weeks. The results were assessed using the Mini-Mental State Examination, the Clinical Global Impression, the Sandoz Clinical Assessment--Geriatric, the Hamilton Depression Scale, the Nuremberg Activities Inventory, the Activities of Daily Living Scale and the modified Trail Making Test. Results: Patients treated with cerebrolysin showed statistically significant improvement in Mini-Mental State Examination scores and the modified Trail Making Test at the end of treatment compared with patients treated with placebo. The Mini-Mental State Examination score was raised by 2.7 points from baseline in patients treated with cerebrolysin. The incidence of treatment-related adverse events with cerebrolysin was low (5%) and comparable to that observed with placebo (8%). Conclusion: Cerebrolysin leads to fast and clinically relevant improvement in some areas of cognitive function in patients with vascular dementia. There were no significant side effects observed during cerebrolysin treatment. Keywords: Cerebrolysin; Efficacy; Vascular Dementia INTRODUCTION Vascular dementia is due to the effects of one or more cerebrovascular accidents (CVAs) on cognitive function. Typically, vascular dementia is characterised by an abrupt onset and stepwise course, documented by history, focal neurological signs and symptoms, and/or imaging studies. The pattern of cognitive deficits is often patchy, depending on which regions of the brain have been destroyed. Certain cognitive functions may be affected early, whereas others remain relatively unimpaired. Vascular dementia is the second most common cause of adult dementia after Alzheimer's disease. Different criteria for inclusion account for reported rates of vascular dementia varying from 4.5% to 39% (Jellinger et al., 1994). As in Alzheimer's disease, the incidence of dementia with evidence of cerebral infarcts increases with age. Vascular disease can damage cerebral tissue through large or small vessel arteriosclerosis, embolus, vasculitis, amyloid angiopathy, or intracranial haemorrhage. In recent years, technical advances in imaging have improved the delineation of cerebral pathology in life and allowed a more precise understanding of the variety of different clinical syndromes that reflect vascular damage to the brain (Sadavoy et al., 1996). These clinical syndromes include: (1) multi-infarct dementia; and (2) strategic infarct dementia (from a strategically important area such as the angular gyrus or the thalamus); and lesions in the white matter (lacunar infarcts, white matter ischaemia, Binswanger's encephalitis). The term 'multi-infarct dementia' implies a large number of small areas of infarction of the grey matter within the cortex, usually from disease of extracerebral vessels, and the clinical picture reflects the cortical damage with dysphasia, dispraxia and agnosia. In strategic infarct dementia, other clinical features are characteristic of their location such as fluent dysphasia in angular gyrus syndrome. Lacunar infarcts are defined pathologically as a complete cavicating infarct not exceeding 10 mm in diameter in the brain stem, central grey nuclei and the white matter, particularly of the frontal lobes (Jacoby et al., 1997). White matter ischaemia refers to a variety of pathological changes, including incomplete infarctions resulting from narrowing of the intracerebral penetrating arterioles. Prevention of vascular dementia, or at least a reduction in incidence, may be attainable if appropriate attention is paid to cardiovascular disease before the overt cerebral insult occurs. …

Glycogen synthase kinase-3 inhibition as a potential pharmacological target for vascular dementia: In silico and in vivo evidence

Targeting Impaired Nutrient Sensing via the Glycogen Synthase Kinase-3 Pathway With Therapeutic Compounds to Prevent or Treat Dementia: A Systematic Review

Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease

Targeting glycogen synthase kinase-3 β for Alzheimer's disease: Recent advances and future Prospects

Targeting Glycogen Synthase Kinase-3Β for Alzheimer's Disease: Recent Advances and Future Prospects

Identification of novel brain penetrant GSK-3β inhibitors toward Alzheimer's disease therapy by virtual screening, molecular docking, dynamic simulation, and MMPBSA analysis

Meridianins and Lignarenone B as Potential GSK3β Inhibitors and Inductors of Structural Neuronal Plasticity

Designing of Dual Inhibitors for GSK-3β and CDK5: Virtual Screening and in Vitro Biological Activities Study

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer's Disease

Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer's therapy

The Efficacy of Cerebrolysin in Patients with Vascular Dementia: Results of a Chinese Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial

Inhibition of histone methyltransferase promotes cognition and mitochondrial function in vascular dementia model

Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3β inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents

Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer's Disease Treatment

Natural compounds from herbs and nutraceuticals as glycogen synthase kinase-3β inhibitors in Alzheimer's disease treatment

Abstract TMP119: Evaluation of Cognitive Function and Plasma Biomarkers in a Microemboli-Based VCID Model in Rats: Applying Clinical Recommendations From MarkVCID and the Lacunar Intervention Trial-2 (LACI-2) to a Preclinical Model

GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

Gastrodin relieves cognitive impairment by regulating autophagy via PI3K/AKT signaling pathway in vascular dementia

Molecular Mechanisms of Lithium Action: Switching the Light on Multiple Targets for Dementia Using Animal Models

Edaravone Dexborneol Alleviates Neuroinflammation by Reducing Neuroglial Cell Proliferation and Suppresses Neuronal Apoptosis/Autophagy in Vascular Dementia Rats

Inhibition of GSK_3β by Iridoid Glycosides of Snowberry (Symphoricarpos albus) Effective in the Treatment of Alzheimer’s Disease Using Computational Drug Design Methods